Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.01 USD
Change Today +1.31 / 4.27%
Volume 870.0
As of 9:30 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (HLUKF) Snapshot

Open
$32.01
Previous Close
$30.70
Day High
$32.01
Day Low
$32.01
52 Week High
08/27/15 - $32.01
52 Week Low
02/9/15 - $18.64
Market Cap
6.3B
Average Volume 10 Days
1.3K
EPS TTM
--
Shares Outstanding
196.6M
EX-Date
03/26/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for H LUNDBECK A/S (HLUKF)

Related News

No related news articles were found.

h lundbeck a/s (HLUKF) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,801 Employees
Last Reported Date: 08/19/15
Founded in 1915

h lundbeck a/s (HLUKF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (HLUKF) Key Developments

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited Announce FDA Accepts a Supplemental New Drug Application for Review of Brintellix (Vortioxetine) Clinical Trial Data

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced the US Food and Drug Administration has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD) to the current product label. Brintellix is currently approved and available in the US for the treatment of MDD in adults. The FDA is expected to take action on this filing by 28 March 2016. Depression includes a range of symptoms including cognitive ones. The cognitive symptoms of depression may go unrecognized by both healthcare providers and patients. Common cognitive complaints include difficulty concentrating, indecisiveness, trouble thinking and forgetfulness. These symptoms are common and many of them often persist between major depressive episodes. According to a three-year prospective study of people treated for depression, cognitive symptoms (defined as diminished ability to think or concentrate and/or indecisiveness) were reported 94% of the time during major depressive episodes and 44% of the time between major depressive episodes (or during periods of partial remission). The sNDA is primarily based on the FOCUS and CONNECT studies, which were specifically designed to assess the effect of Brintellix on certain aspects of cognitive function in adult patients with MDD utilizing objective measures of cognitive function. These two 8-week, randomized, double-blind, placebo-controlled studies of Brintellix 10 and 20 mg/day used a well-established neuropsychological test (the Digit Symbol Substitution Test or DSST). The DSST performance measurement involves executive function, processing speed and attention. The FDA approved Brintellix on 30 September 2013 for the treatment of MDD in adults. Brintellix is furthermore approved in 55 countries (including Europe, Canada, Chile, Mexico, Argentina, South Korea, Turkey, Australia, Hong Kong, Singapore and South Africa). It is available in approximately 30 countries to date.

Otsuka America Pharmaceutical, Inc. and Lundbeck Announces U.S. Food and Drug Administration Approves Deltoid Injection Site for Abilify Maintena

Otsuka America Pharmaceutical, Inc. and Lundbeck announced that the U.S. Food and Drug Administration (FDA) has expanded the label of Abilify Maintena (aripiprazole) for extended-release injectable suspension to include a new injection site, the deltoid muscle of the arm. Healthcare providers will now have the option for either a gluteal or deltoid injection site for administering Abilify Maintena to patients with schizophrenia. Abilify Maintena is the first and only once-monthly injection of a dopamine D2 partial agonist (the first injection is accompanied by 14 days of oral antipsychotic therapy) approved for the treatment of adults with schizophrenia. It was originally indicated for only gluteal injection when approved by the FDA in February 2013. The approval of the deltoid injection site was based on two studies that evaluated the safety and tolerability and pharmacokinetics of Abilify Maintena administered in the deltoid muscle compared to the gluteal muscle in adult patients with schizophrenia. This new deltoid administration offering for Abilify Maintena is scheduled to be commercially available in the fall of 2015. The pharmacokinetics, safety and tolerability of Abilify Maintena administered in the deltoid muscle compared to the gluteal muscle was evaluated in two, open-label studies in stable patients aged 18-64 years with a current diagnosis of schizophrenia. One study was a randomized, single-dose, parallel-arm, relative bioavailability study comparing the pharmacokinetic parameters of Abilify Maintena 400 mg after injection in the deltoid muscle of 17 patients, with the injection in the gluteal muscle of 18 patients. The second study was a multiple-dose, parallel-arm study designed to evaluate the safety and tolerability of Abilify Maintena 400 mg injections in the deltoid muscle, and to derive pharmacokinetic parameters following five monthly injections. In this study, 141 patients were randomized to the study and 138 received at least one dose of Abilify Maintena 400 mg injection either in the deltoid (N=71) or gluteal (N=67) muscle; subsequent doses were administered to all patients in the deltoid muscle. Of the patients who received at least one dose of Abilify Maintena, 97.1% of subjects had no dose adjustment; only four patients had a dose reduction to 300 mg. In an open-label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site pain was observed in both groups at approximately equal rates. Furthermore, in the second study, multiple injections of Abilify Maintena 400 mg in the deltoid muscle resulted in comparable maximal- and minimal-plasma concentrations and comparable exposures of aripiprazole compared with injections in the gluteal muscle, as measured in earlier studies. These data were presented earlier this year at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida.

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. Announces US Food and Drug Administration Approves Rexulti (Brexpiprazole) as an Adjunctive Therapy

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced that the US Food and Drug Administration approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder and as a treatment for adults with schizophrenia. Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the US in early August 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUKF:US $32.01 USD +1.31

HLUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ipsen SA €59.55 EUR +3.49
Lupin Ltd 1,900 INR +89.45
Meda AB kr128.10 SEK +2.10
Orion Oyj €35.36 EUR +0.33
Recordati SpA €21.44 EUR +0.24
View Industry Companies
 

Industry Analysis

HLUKF

Industry Average

Valuation HLUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.